Abstract
Acetylcholinesterase inhibitors are regarded as the most promising approach to treat Alzheimer’s disease (AD). However, their anticipated side effects limit their usage. Present investigations involved the incorporation of the newly synthesized 2-naphthol derivatives (PP-81 and PP-84) into solid lipid nanoparticles (SLNs) to improve their accessibility to the brain and enhance the levels of acetylcholine. Drug loaded SLNs of PP-81 and PP-84 showed that average particle size of 138 nm and 186 nm, positive zeta potential and total drug content of 86.13 ± 0.49 % w/v and 81.18 ± 0.78 % w/v respectively were obtained using microemulsification technique. The particles were found to be spherical in shape, with high drug entrapment (91.28 ± 0.14 % w/w, PP-81 and 70.94 ± 0.59 % w/w, PP-84) at 10 % drug loading. Confirmation of SLNs formation was performed using DSC and PXRD studies. In in vitro release study diffusion phenomenon was predominant and was prolonged up to 24 h. Elevated plus maze test was carried out to evaluate memory acquisition and retention; post treatment with SLNs and respective free drugs in scopolamine induced spatial memory deficit in mice. Results indicated a significant increase (p < 0.05) in percentage retention of memory and learning with PP-81 and PP- 84 SLNs respectively at 20 mg/kg. It can be an optimized potential therapeutic and brain targeting approach for the treatment of AD.
Keywords: Alzheimer’s disease, acetylcholinesterase inhibitors, microemulsification method, solid lipid nanoparticles, DSC, PXRD, elevated plus maze.
Current Drug Therapy
Title:Newly Synthesized Acetylcholinesterase Inhibitors for Alleviating Alzheimer’s Disease using Solid Lipid Nanoparticles
Volume: 9 Issue: 2
Author(s): Rohit Makkar, Paramveer Singh, Chhanda C. Danta, Vandita Kakkar, Indu P. Kaur and Poonam Piplani
Affiliation:
Keywords: Alzheimer’s disease, acetylcholinesterase inhibitors, microemulsification method, solid lipid nanoparticles, DSC, PXRD, elevated plus maze.
Abstract: Acetylcholinesterase inhibitors are regarded as the most promising approach to treat Alzheimer’s disease (AD). However, their anticipated side effects limit their usage. Present investigations involved the incorporation of the newly synthesized 2-naphthol derivatives (PP-81 and PP-84) into solid lipid nanoparticles (SLNs) to improve their accessibility to the brain and enhance the levels of acetylcholine. Drug loaded SLNs of PP-81 and PP-84 showed that average particle size of 138 nm and 186 nm, positive zeta potential and total drug content of 86.13 ± 0.49 % w/v and 81.18 ± 0.78 % w/v respectively were obtained using microemulsification technique. The particles were found to be spherical in shape, with high drug entrapment (91.28 ± 0.14 % w/w, PP-81 and 70.94 ± 0.59 % w/w, PP-84) at 10 % drug loading. Confirmation of SLNs formation was performed using DSC and PXRD studies. In in vitro release study diffusion phenomenon was predominant and was prolonged up to 24 h. Elevated plus maze test was carried out to evaluate memory acquisition and retention; post treatment with SLNs and respective free drugs in scopolamine induced spatial memory deficit in mice. Results indicated a significant increase (p < 0.05) in percentage retention of memory and learning with PP-81 and PP- 84 SLNs respectively at 20 mg/kg. It can be an optimized potential therapeutic and brain targeting approach for the treatment of AD.
Export Options
About this article
Cite this article as:
Makkar Rohit, Singh Paramveer, C. Danta Chhanda, Kakkar Vandita, P. Kaur Indu and Piplani Poonam, Newly Synthesized Acetylcholinesterase Inhibitors for Alleviating Alzheimer’s Disease using Solid Lipid Nanoparticles, Current Drug Therapy 2014; 9 (2) . https://dx.doi.org/10.2174/1574885509666140804222101
DOI https://dx.doi.org/10.2174/1574885509666140804222101 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
One Hundred Faces of Cyclopamine
Current Pharmaceutical Design Glucose Tolerance: Hypothesis Testing on Malaysian Diabetic Community
Current Diabetes Reviews Molecular Design of Bioconjugated Cell Adhesion Peptide with a Water-Soluble Polymeric Modifier for Enhancement of Antimetastatic Effect
Current Drug Targets Novel Gastrin Receptor-Directed Contrast Agents - Potential in Brain Tumor Magnetic Resonance Imaging
Medicinal Chemistry Neuronal Excitability in Epileptogenic Zones Regulated by the Wnt/ Β-Catenin Pathway
CNS & Neurological Disorders - Drug Targets Phenanthridine Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Design, Synthesis and Biological Evaluation
Current Computer-Aided Drug Design Elucidation of Glutamate Transporter Functions Using Selective Inhibitors
Central Nervous System Agents in Medicinal Chemistry 6-Oxo-Morphinane Oximes: Pharmacology, Chemistry and Analytical Application
Current Medicinal Chemistry LPS-induced Murine Neuroinflammation Model: Main Features and Suitability for Pre-clinical Assessment of Nutraceuticals
Current Neuropharmacology Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry CCR1 Antagonists: What Have We Learned From Clinical Trials
Current Topics in Medicinal Chemistry Pharmacotherapy and the Psychobiological Model of Personality: Implications for DSM-5
Current Psychopharmacology Associations between Alzheimer’s Disease and Blood Homocysteine, Vitamin B<sub>12</sub>, and Folate: A Case-Control Study
Current Alzheimer Research Metabolism of Dietary Flavonoids in Liver Microsomes
Current Drug Metabolism Regulatory T Cells as Targets for Immunotherapy of Autoimmunity and Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Editorial [Hot topic: Immunological Regulation of the Central Nervous System: From Physiological to Pathological Processes (Guest Editor: Oscar Gonzalez-Perez)]
Current Immunology Reviews (Discontinued) Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice
CNS & Neurological Disorders - Drug Targets Quantitative Structure Activity Relationship and Design of Phenyl Alkyl Ketone Derivatives as Inhibitors of Phosphodiesterase 4
Current Enzyme Inhibition Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Economics of Pharmacogenomics: Rethinking Beyond QALYs?
Current Pharmacogenomics and Personalized Medicine